Recent advances in microneedles-mediated transdermal delivery of protein and peptide drugs.
10.1016/j.apsb.2021.03.003
- Author:
Ting LIU
1
;
Minglong CHEN
1
;
Jintao FU
1
;
Ying SUN
1
;
Chao LU
2
;
Guilan QUAN
2
;
Xin PAN
1
;
Chuanbin WU
2
Author Information
1. School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
2. College of Pharmacy, Jinan University, Guangzhou 510632, China.
- Publication Type:Review
- Keywords:
Cancer;
Clinic;
Diabetes;
Infectious diseases;
Microneedles;
Peptides;
Proteins;
Transdermal drug delivery
- From:
Acta Pharmaceutica Sinica B
2021;11(8):2326-2343
- CountryChina
- Language:English
-
Abstract:
Proteins and peptides have become a significant therapeutic modality for various diseases because of their high potency and specificity. However, the inherent properties of these drugs, such as large molecular weight, poor stability, and conformational flexibility, make them difficult to be formulated and delivered. Injection is the primary route for clinical administration of protein and peptide drugs, which usually leads to poor patient's compliance. As a portable, minimally invasive device, microneedles (MNs) can overcome the skin barrier and generate reversible microchannels for effective macromolecule permeation. In this review, we highlighted the recent advances in MNs-mediated transdermal delivery of protein and peptide drugs. Emphasis was given to the latest development in representative MNs design and fabrication. We also summarize the current application status of MNs-mediated transdermal protein and peptide delivery, especially in the field of infectious disease, diabetes, cancer, and other disease therapy. Finally, the current status of clinical translation and a perspective on future development are also provided.
